Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Deborah Hibbett, Senior Vice President, Head of Global Corporate Affairs and Sustainability, Plasma-Derived Therapies at Takeda, shared on LinkedIn:
”The updated European Medicines Agency’s Union List of Critical Medicines now includes a plasma-derived therapy for hemophilia patients with inhibitors.
This addition underscores that reliable, uninterrupted access to critical medicines – including this product and the other listed plasma-derived therapies – is essential for patients, families and healthcare systems.
Takeda celebrates this update as we are also committed to the bleeding disorders community and to creating value through sustainable, equitable access – including our renewed collaboration with the WFH Humanitarian Aid Program and the work highlighted in Takeda’s 2025 Access to Medicines Update.
Thank you to the healthcare community, patient advocates and partners who continue to advance security of supply and equity in care every day.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch